Journal articleJ Gastrointest Oncol2015

Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis.

DOI 10.3978/j.issn.2078-6891.2015.041 ↗ OpenAlex, retrieved 5 November 2026

Journal: J Gastrointest Oncol
Published: 1 October 2015
Citations: 24
Type: Article

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 2

BackgroundThe First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients NCT05168527 ↗
BackgroundRetrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer NCT04133155 ↗